OPTIBIOTIX HLTH PLC LS-02
Research OPTIBIOTIX HLTH PLC LS-02 (OB3) on Bullrun: market cap EUR 6.66M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerOB3
- ExchangeF
- CountryUnited Kingdom
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 6.66M
- Financial periodFY2025
- RevenueGBP 1.17M
- Revenue growth34.0%
- Net income-GBP 3.89M
- Free cash flow-GBP 1.77M
- Gross margin52.7%
Valuation Snapshot
latest market cap is EUR 6.66M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | GBP 1.17M | -GBP 3.89M | -GBP 1.77M | 52.7% | -0.04 | GBP 1.04M | n/a | GBP 6.28M |
| FY2024 | GBP 870.00K | -GBP 1.81M | -GBP 1.77M | 38.0% | -0.02 | GBP 739.00K | n/a | GBP 8.40M |
| FY2023 | GBP 644.00K | -GBP 2.04M | -GBP 1.53M | 49.7% | -0.02 | GBP 635.00K | n/a | GBP 8.87M |
| FY2022 | GBP 457.00K | GBP 2.59M | -GBP 1.28M | 53.4% | 0.03 | GBP 1.05M | GBP 0 | GBP 10.91M |
| FY2021 | GBP 2.21M | GBP 6.26M | -GBP 1.76M | 50.7% | 0.07 | GBP 2.01M | GBP 819.00K | GBP 18.14M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 6.66M | n/a | n/a | n/a |
About OPTIBIOTIX HLTH PLC LS-02
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is OPTIBIOTIX HLTH PLC LS-02's market cap?
OPTIBIOTIX HLTH PLC LS-02's market capitalization is EUR 6.66M.
What does OPTIBIOTIX HLTH PLC LS-02 do?
OptiBiotix Health Plc, a life sciences company, engages in the discovery and development of microbiome modulation products in the United Kingdom, the United States, India, China, and internationally. The company identifies and develops microbial strains, compounds, and formulations for use in food ingredients, supplements, and active compounds that can impact human physiology and derive potential health benefits.